Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Artemis 2 captures historic 'Earthset' photo | Space photo of the day for April 7, 2026 - 2People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- 3Figure out How to Remain Persuaded During Your Internet based Degree Program
- 4Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- 5China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- US measles cases surpass 2,000, highest in 30 years: CDC
- Bestselling author Colleen Hoover reveals cancer journey
- Manual for Mountain Objections on the planet
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- 6 Eyewear Brands Worth Purchasing
- African Forests Have Become a Source of Carbon Emissions
- Online business Stages for Little Retailers
- Figure out How to Really focus on Your Dental Inserts for Durable Outcomes
